Aveanna Healthcare shares fall 6% despite third quarter beat
Aveanna Healthcare (AVAH) reported Q3 earnings of $0.23 per share, beating estimates by $0.02, with revenue of $695.5M, up 11.8% YoY. Despite this, shares fell 6.04% pre-market due to fiscal 2026 guidance that aligned with analyst expectations. The company raised its full-year revenue guidance to over $2.695B and EBITDA guidance to over $374M. All three business segments contributed to revenue growth, and net income rose to $45.5M from $14.1M YoY.
How this was made
The 30-second read
Why it matters
The modest guidance lift suggests limited growth momentum, prompting investors to sell, which may create a buying opportunity if the market overreacts.
Market read
Earnings beat with weak guidance leads to immediate price pressure; traders may act on the sell‑off.
What to watch
Strong cash flow generation and expanding margins may support longer‑term upside despite short‑term sell‑off.
Background
Aveanna Healthcare (NASDAQ:AVAH) posted Q3 results that beat EPS and revenue estimates, yet its FY2026 guidance barely exceeded consensus, causing a pre‑market decline.
Ticker impact
Shares fell 6% in pre‑market after Aveanna Healthcare reported Q3 earnings beat but guidance that disappointed investors.
downward pressure as market prices in the modest guidance outlook
The company raised full‑year revenue and EBITDA guidance only marginally above consensus, leading to a 6% pre‑market decline.
Market effects
Home‑care and health‑services sector may see broader scrutiny on guidance expectations.
U.S. small‑cap health‑services stocks could face short‑term pressure.
Limited; primarily affects U.S. investors focused on Aveanna and comparable providers.
Counterpoint
If guidance is viewed as a floor rather than a disappointment, the stock could rebound on the earnings beat.
Key entities
- companyAveanna Healthcare Holdings Inc.
Home‑care provider reporting Q3 earnings and FY2026 guidance.
- executiveJeff Shaner
CEO of Aveanna Healthcare who commented on the results.

